A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer

Cheng, Jian; Ha, Minwen; Wang, Yadi; Sun, Jing; Chen, Junchen; Wang, Yue; Tong, Chunyan

doi:10.1007/s00432-011-1090-1

Cited by 31 publications

(23 citation statements)

References 24 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The predictive value of ERCC1 expression in platinum-based chemotherapy responses has been reported in various cancers such as non-small cell cancer, ovarian cancer, and cervical cancer, as well as BC (Dabholkar et al, 1994;Kong et al, 2006;Bellmunt et al, 2007;Chen et al, 2010;Hoffmann et al, 2010;Okuda et al, 2011;Park et al, 2011;Cheng et al, 2012;Lv et al, 2014). A systemic review published in 2012 further confirmed the predictive value of ERCC codon C118T polymorphism in advanced colorectal patients treated with platinum-based chemotherapy in the Asian population.…”

Section: Discussionmentioning

confidence: 79%

“…Polymorphism in the ERCC1 genes could also affect its expression, which may influence the chemotherapy responses in various cancers. A study by Cheng et al (2012) reported that the C118T polymorphism of ERCC1 is associated with patient responses to cisplatin-based chemotherapy in late-stage non-small cell lung cancer. The response rate of patients carrying an ERCC1 codon 118 C/C allele was more than two-fold higher as compared with that of patients with either the C/T or T/T genotype.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

Cai

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinumbased chemotherapy in patients with late-stage bladder cancer. A total of 41 eligible patients histologically confirmed as having stage IV muscleinvasive transitional cell carcinoma of the bladder were treated with platinum-based chemotherapy for 2-6 cycles. The genotypes of patients were determined by PCR amplification of genomic DNA followed by restriction enzyme digestion. Positive responses were categorized as complete and partial responses. In addition, progression-free survival (PFS) and overall survival (OS) were also determined as indicators of long-term outcomes. The genotype frequencies of C/C, C/T and T/T genotypes were 56.1, 34.1, and 9.8%, respectively. Positive response was observed in 14 patients (34.1%), while 27 patients (65.9%) were negative responders. As compared with individuals carrying the C/T and T/T genotypes, those with the C/C genotype had significantly improved short-term treatment responses (P = 0.018). The median PFS of patients carrying the C/C genotype was 6.3 months, while that of patients with C/T and T/T genotypes was 4.2 months (P = 0.023). Moreover, the median OS for patients carrying the C/C genotype was also longer as compared with that of patients carrying C/T and T/T (11.7 months vs 8.5 months, P = 0.040). Our results indicated that the ERCC1 codon 118 polymorphism may have predictive potential for chemotherapy treatment responses in late-stage bladder cancer patients.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

Cai

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Polymorphisms have also been shown to be important. Patients with at least one C allele at codon 118 of the ERCC1 gene have a greater response to cisplatin treatment [98] and better overall survival [99] than those with a T allele. A phase II trial of 42 patients demonstrated significant improvements in overall response rates when NSCLC patients had their chemotherapy regime customised based on their genotype for two SNPs (118T/C and 8092C/A) in the ERCC1 gene and two in the ribonucleotide reductase M1 gene(À37C/A and À524T/C) [100].…”

Section: Excision Repair Cross-complimentary Group I (Ercc1)mentioning

confidence: 99%

The role of DNA repair pathways in cisplatin resistant lung cancer

O’Grady

Finn

Cuffe

et al. 2014

Cancer Treatment Reviews

119

View full text Add to dashboard Cite

“…Ren et al (2012) indicated that AAT codons of ERCC1 rs11615 might be a predictive marker for patients with non-small cell lung carcinoma (NSCLC) treated with platinum-based chemotherapy. Cheng et al (2012) found that the C allele of ERCC1 rs11615 polymorphism was associated with longer response to cisplatin-based chemotherapy in treatment of last-stage NSCLC than T allele. Gao et al (2014) found that the ERCC1 polymorphisms rs11615 and rs3212986 were negatively associated with response to chemotherapy and survival time of patients with advanced NSCLC.…”

Section: Discussionmentioning

confidence: 92%

“…Multiple previous studies have reported that ERCC1 and ERCC2 were associated with the response to cisplatin-based chemotherapy and clinical outcome in several cancers (Kamikozuru et al, 2008;Park et al, 2011;Cheng et al, 2012;Ren et al, 2012;Chen et al, 2013;Rumiato et al, 2013;Gao et al, 2014;Li et al, 2014b). Park et al (2011) reported that the ERCC1 rs3212986 polymorphism was correlated with treatment outcome of metastatic gastric cancer treated with cisplatin-based chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma

Jiang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We aimed to evaluate the influence of four SNPs in ERCC1 and ERCC2 on the response to cisplatin-based treatment and on clinical outcome in patients with osteosarcoma. We identified 186 patients with osteosarcoma diagnosed between April 2009 and April 2011 who were eligible for inclusion in our study. Genotyping of ERCC1 rs11615, rs3212986, and rs2298881; and ERCC2 rs1799793 and rs13181 was conducted by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. By conditional logistic regression analysis, patients carrying the CC genotypes of ERCC1 rs11615 and rs2298881 were shown to be more likely to have good response to chemotherapy when compared with patients carrying wildtype genotypes; the ORs (95%CIs) were 2.56 (1.02-7.35) and 3.01 (1.07-9.71), respectively. By Cox regression analysis, individuals carrying the CC genotype of ERCC1 rs11615 were associated with longer overall survival time and decreased risk of death from osteosarcoma; the hazards 10146 Z.H. Cao et al. ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (3): 10145-10151 (2015) ratio (95%CI) was 0.32 (0.07-0.98). In summary, our results suggested that the ERCC1 rs11615 and rs2298881 polymorphisms play important roles in the response to chemotherapy mediated by the DNA repair pathway and in the clinical outcome of osteosarcoma.

show abstract

A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer

Cited by 31 publications

References 24 publications

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

The role of DNA repair pathways in cisplatin resistant lung cancer

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma

Contact Info

Product

Resources

About